País: Reino Unido
Língua: inglês
Origem: MHRA (Medicines & Healthcare Products Regulatory Agency)
Isavuconazonium sulfate
Pfizer Ltd
Isavuconazonium sulfate
200mg
Powder for solution for infusion
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 05020100; GTIN: 7640137531201
1 Plfeet: 2018-0035141 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT CRESEMBA 200 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION Isavuconazole This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Cresemba is and what it is used for 2. What you need to know before you use Cresemba 3. How to use Cresemba 4. Possible side effects 5. How to store Cresemba 6. Contents of the pack and other information 1. WHAT CRESEMBA IS AND WHAT IT IS USED FOR WHAT CRESEMBA IS Cresemba is an anti-fungal medicine that contains the active substance isavuconazole. HOW CRESEMBA WORKS Isavuconazole works by killing or stopping the growth of the fungus, which causes the infection. WHAT CRESEMBA IS USED FOR Cresemba is used in adults to treat the following fungal infections: - invasive aspergillosis, caused by a fungus in the ‘Aspergillus’ group; - mucormycosis, caused by a fungus beloning to the ‘Mucorales’ group in patients for whom a treatment with amphotericin B is not appropriate. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE CRESEMBA _ _ DO NOT USE CRESEMBA: - if you are allergic to isavuconazole or any of the other ingredients of this medicine (listed in section 6), - if you have a heart beat problem called ‘familial short QT syndrome’, - IF YOU ARE USING ANY OF THE FOLLOWING MEDICINES: - ketoconazole, used for fungal infections, - high doses of ritonavir (400 mg every 12 hours), used for HIV, - rifampicin, rifabutin, used Leia o documento completo
CRESEMBA 200 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION Summary of Product Characteristics Updated 29-Mar-2017 | Basilea Pharmaceutica International Ltd This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. Name of the medicinal product CRESEMBA 200 mg powder for concentrate for solution for infusion 2. Qualitative and quantitative composition Each vial contains 200 mg isavuconazole (as 372.6 mg isavuconazonium sulfate). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Powder for concentrate for solution for infusion White to yellow powder 4. Clinical particulars 4.1 Therapeutic indications CRESEMBA is indicated in adults for the treatment of • invasive aspergillosis • mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1) Consideration should be given to official guidance on the appropriate use of antifungal agents. 4.2 Posology and method of administration Posology _Loading dose_ The recommended loading dose is one vial after reconstitution and dilution (equivalent to 200 mg of isavuconazole) every 8 hours for the first 48 hours (6 administrations in total). _Maintenance dose_ The recommended maintenance dose is one vial after reconstitution and dilution (equivalent to 200 mg of isavuconazole) once daily, starting 12 to 24 hours after the last loading dose. Duration of therapy should be determined by the clinical response (see section 5.1). For long-term treatment beyond 6 months, the benefit-risk balance should be carefully considered (see sections 5.1 and 5.3). _Switch to oral isavuconazole_ CRESEMBA is also available as hard capsules containing 100 mg isavuconazole, equivalent to 186 mg isavuconazonium sulfate. On the basis of the high oral bioavailability (98%, see section 5.2), switching between intravenous and oral administration i Leia o documento completo